TY  - CHAP
M1  - Book, Section
TI  - Clinical Evaluation, Diagnosis, and Staging of Lung Cancer
A1  - Chang, Lydia
A1  - Rivera, M. Patricia
A2  - Grippi, Michael A.
A2  - Elias, Jack A.
A2  - Fishman, Jay A.
A2  - Kotloff, Robert M.
A2  - Pack, Allan I.
A2  - Senior, Robert M.
A2  - Siegel, Mark D.
Y1  - 2015
N1  - 
T2  - Fishman's Pulmonary Diseases and Disorders, 5e
AB  - Patients  who  present  with  suspected  lung  cancer  require  a  detailed  clinical  evaluation  followed  by  noninvasive  testing  and  invasive  procedures  to  establish  both  the  histopathologic  diagnosis  as  well  as  disease  stage.  Historically,  great  emphasis  has  been  placed  upon  the  differentiation  of  small-cell  lung  cancer  (SCLC)  from  non–small-cell  lung  cancer  (NSCLC).  SCLC,  which  accounts  for  14%  of  bronchogenic  carcinomas,  is  histologically  and  clinically  distinct  from  NSCLC.1  NSCLCs  have  been  traditionally  regarded  as  a  fairly  uniform  group  of  cancers.  However,  it  has  become  increasingly  evident  that  NSCLCs  are  comprised  of  clinically,  pathologically,  and  molecularly  diverse  tumors  that  respond  to  different  therapeutic  agents  based  on  specific  histologic  phenotypes  and  molecular  characteristics.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/16
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1122367341
ER  -